2026-06-11

HY spreads at distress levels - 705bps, recession-associated

Phase 3 trial terminated early - JOHNSON A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hyd

Phase 3 trial terminated early - JOHNSON A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patie

Phase 3 trial terminated early - JOHNSON Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers

Phase 3 trial terminated early - JOHNSON A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus P

Phase 3 trial terminated early - JOHNSON A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With

Phase 3 trial terminated early - ELI A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Phase 3 trial terminated early - ELI On Open-Label Study in Participants With Systemic Lupus Erythematosus

Phase 3 trial terminated early - ELI A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adole

Phase 3 trial terminated early - ELI Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

Phase 3 trial terminated early - BRISTOL An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness,

Phase 3 trial terminated early - BIOGEN Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma

Phase 3 trial terminated early - BIOGEN Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Pat

Phase 3 trial terminated early - BIOGEN A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With A

Phase 3 trial terminated early - BIOGEN Phase 3 Extension Study of Dexpramipexole in ALS

Phase 3 trial terminated early - BIOGEN Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclero

Phase 3 trial terminated early - AMGEN Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onse

Phase 3 trial terminated early - AMGEN Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or R

Phase 3 trial terminated early - INCYTE Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Phase 3 trial terminated early - INCYTE GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Gr

Phase 3 trial terminated early - REGENERON CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subje

Phase 3 trial terminated early - REGENERON A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections

Phase 3 trial terminated early - REGENERON An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotr

Phase 3 trial terminated early - REGENERON Long Term Safety Study of PRALUENT

Phase 3 trial terminated early - Medtronic Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Elut

Phase 3 trial terminated early - Medtronic Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke

Phase 3 trial terminated early - Medtronic Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients

Phase 3 trial terminated early - Medtronic X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suf

Phase 3 trial terminated early - Medtronic Combining Observational and Physiologic Sedation Assessment Tools

FDA approves drug (AbbVie) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

Phase 3 trial terminated early - AbbVie A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Tr

Phase 3 trial terminated early - AbbVie A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer P

Phase 3 trial terminated early - AbbVie Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Compl

FDA approves drug (AbbVie) - new revenue stream

Phase 3 trial terminated early - ABBOTT Kaletra and Viread in Antiretroviral Naïve Patients

Phase 3 trial terminated early - ABBOTT ESCAPE Migraine Trial

Phase 3 trial terminated early - ABBOTT Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemothera

Phase 3 trial terminated early - PFIZER Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of

Phase 3 trial terminated early - PFIZER The Effect of Lipitor on Aortic Stenosis

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

FDA approves drug (PFIZER) - new revenue stream

Phase 3 trial terminated early - PFIZER Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection

Phase 3 trial terminated early - PFIZER Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN P

FDA approves drug (PFIZER) - new revenue stream

Phase 3 trial terminated early - PFIZER Pregabalin for Abdominal Pain From Adhesions

Phase 3 trial terminated early - Merck A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With

Phase 3 trial terminated early - Merck Alvimopan as Rescue in Post op Ileus

Phase 3 trial terminated early - Merck Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doraviri

Phase 3 trial terminated early - Merck TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and A

Phase 3 trial terminated early - Merck Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Particip

Phase 3 trial terminated early - Merck Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacterem

Phase 3 trial terminated early - Merck Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH

Phase 3 trial terminated early - GILEAD Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following P

Phase 3 trial terminated early - GILEAD Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants

Phase 3 trial terminated early - GILEAD Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic

Phase 3 trial terminated early - GILEAD Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Pr

CONOCOPHILLIPS search volume spiked +35 pts - unusual interest

5 congress members traded HUBB - net BEAR (0B/0S)

6 congress members traded TSCO - net BEAR (0B/0S)

5 congress members traded CHRW - net BEAR (0B/0S)

OSINT: Canada proposes ban on social media for under‑16s

CONOCOPHILLIPS search volume spiked +35 pts - unusual interest

5 congress members traded CHRW - net BEAR (0B/0S)

6 congress members traded TSCO - net BEAR (0B/0S)

5 congress members traded HUBB - net BEAR (0B/0S)

Beat consensus by 10.6% - EPS $7.74 vs $6.9976 estimate

Q1-2027: Beat consensus by 20.1% - EPS $-0.55 vs $-0.6885 estimate

Q3-2026: Beat consensus by 82.5% - EPS $-0.01 vs $-0.0571 estimate

Q1-2027: Beat consensus by 49.9% - EPS $0.43 vs $0.2868 estimate

Q1-2027: Missed consensus by 5.6% - EPS $0.1 vs $0.1059 estimate

Missed consensus by 66.7% - EPS $-5.1 vs $-3.06 estimate

Missed consensus by 47.1% - EPS $-6.3 vs $-4.284 estimate

Missed consensus by 72.1% - EPS $-4.74 vs $-2.754 estimate

Q3-2025: Beat consensus by 15.0% - EPS $-1.64 vs $-1.9302 estimate

Q4-2025: Beat consensus by 8.0% - EPS $-1.21 vs $-1.3152 estimate

Beat consensus by 60.4% - EPS $-0.055 vs $-0.139 estimate

Q4-2024: Missed consensus by 7.4% - EPS $-0.17 vs $-0.1583 estimate

Q3-2024: Missed consensus by 43.9% - EPS $-0.1 vs $-0.0695 estimate

Q4-2026: Missed consensus by 129.3% - EPS $-0.41 vs $1.3974 estimate

5 congress members traded CHRW - net BEAR (0B/0S)

6 congress members traded TSCO - net BEAR (0B/0S)

5 congress members traded HUBB - net BEAR (0B/0S)

Q1-2026: Missed consensus by 623.1% - EPS $-0.41 vs $-0.0567 estimate

Q3-2025: Beat consensus by 15.5% - EPS $0.14 vs $0.1212 estimate

Q4-2025: Beat consensus by 76.9% - EPS $0.15 vs $0.0848 estimate

Q1-2026: Missed consensus by 11.4% - EPS $0.11 vs $0.1241 estimate

Beat consensus by 98.4% - EPS $1.72 vs $0.867 estimate

Q1-2026: Missed consensus by 56.5% - EPS $0.44 vs $1.0124 estimate

Q2-2025: Beat consensus by 108.2% - EPS $1.55 vs $0.7446 estimate

Q4-2025: Missed consensus by 31.7% - EPS $0.61 vs $0.8925 estimate

Q4-2025: Beat consensus by 240.3% - EPS $0.18 vs $0.0529 estimate

Q3-2026: Beat consensus by 9.2% - EPS $-0.45 vs $-0.4957 estimate

Q2-2026: Missed consensus by 11.2% - EPS $-0.54 vs $-0.4855 estimate

Q4-2025: Beat consensus by 14.7% - EPS $-0.432 vs $-0.5066 estimate

Q4-2025: Beat consensus by 5.3% - EPS $0.054 vs $0.0513 estimate

Missed consensus by 9.5% - EPS $-38.19 vs $-34.884 estimate

Q2-2024: Missed consensus by 107.6% - EPS $-105.83 vs $-50.9694 estimate

Q1-2024: Beat consensus by 15.2% - EPS $-68.4 vs $-80.6208 estimate

Missed consensus by 71.6% - EPS $-6.65 vs $-3.876 estimate

Missed consensus by 48.3% - EPS $0.03 vs $0.058 estimate

Q2-2026: Beat consensus by 89.3% - EPS $0.16 vs $0.0845 estimate

Q1-2026: Beat consensus by 52.2% - EPS $0.098 vs $0.0644 estimate

Q3-2026: Missed consensus by 38.6% - EPS $-0.07 vs $-0.0505 estimate

Beat consensus by 2174.5% - EPS $1.16 vs $0.051 estimate

Q1-2027: Beat consensus by 6.2% - EPS $2.01 vs $1.8922 estimate

Q4-2026: Missed consensus by 349.4% - EPS $-0.39 vs $0.1564 estimate

Beat consensus by 43.8% - EPS $-0.4 vs $-0.712 estimate

Missed consensus by 31.1% - EPS $-1 vs $-0.763 estimate

Q4-2013: Missed consensus by 67.0% - EPS $-2 vs $-1.1975 estimate

Q3-2025: Missed consensus by 5.0% - EPS $-0.63 vs $-0.5999 estimate

Beat consensus by 5.2% - EPS $-0.551 vs $-0.581 estimate

Q4-2025: Missed consensus by 5.5% - EPS $-0.586 vs $-0.5554 estimate

Q1-2026: Beat consensus by 27.0% - EPS $-0.369 vs $-0.5057 estimate

Q3-2026: Missed consensus by 391.4% - EPS $-0.47 vs $0.1613 estimate

Q4-2026: Missed consensus by 291.9% - EPS $-0.68 vs $-0.1735 estimate

Missed consensus by 268.0% - EPS $-0.13 vs $0.0774 estimate

5 congress members traded CHRW - net BEAR (0B/0S)

5 congress members traded HUBB - net BEAR (0B/0S)

6 congress members traded TSCO - net BEAR (0B/0S)

Q1-2026: EPS $-0.48 vs $-0.0408 estimate, -0.44 on a near-zero consensus

Q4-2026: EPS $0.0839 vs $0.0245 estimate, +0.06 on a near-zero consensus

Q2-2025: EPS $0.03 vs $0.0466 estimate, -0.02 on a near-zero consensus

Q3-2025: EPS $0.03 vs $0.0491 estimate, -0.02 on a near-zero consensus

Q1-2026: EPS $0.12 vs $0.0464 estimate, +0.07 on a near-zero consensus

Q2-2025: EPS $0.016 vs $0.0255 estimate, -0.01 on a near-zero consensus

Q3-2025: EPS $0.034 vs $0.0286 estimate, +0.01 on a near-zero consensus

Q1-2026: EPS $0.023 vs $0.0316 estimate, -0.01 on a near-zero consensus

EPS $-0.06 vs $0.0408 estimate, -0.10 on a near-zero consensus

EPS $-0.17 vs $-0.0202 estimate, -0.15 on a near-zero consensus

Q1-2026: EPS $0.04 vs $0.0051 estimate, +0.03 on a near-zero consensus

Gold +3.18% - significant rally

OSINT: Explosion reported off Iran's southern coast near Sirik, cause unknown

OSINT: US Signals Possible End to Birthright Citizenship

OSINT: Iran launches >30 missiles at Jordan, ceasefire deemed void

OSINT: US Strikes Trigger Blasts in Iran's Sirik, Raising Regional Tension

Oil -3.10% - significant selloff

Gold +1.29% - significant rally

Oil -1.21% - significant selloff

Brazil Minas Gerais: crop water stress detected (2.5σ above baseline) - potential KC=F supply pressure

Oil +1.06% - significant rally

GOLD RSI 22.8 - oversold (crossed below 30)

BTC open interest -45.5% - OI collapse

SOL open interest -23.1% - OI collapse

ETH open interest -62.7% - OI collapse

ETH open interest +219.3% - OI surge

SOL open interest -64.4% - OI collapse

BTC open interest -42.5% - OI collapse

BTC open interest -47.3% - OI collapse

ETH open interest -62.7% - OI collapse

SOL open interest -21.6% - OI collapse

SOL open interest +258.2% - OI surge

ETH open interest +229.2% - OI surge

BTC open interest +228.8% - OI surge

ETH DEX volume/liquidity ratio elevated (0.51x) - strong on-chain trading activity

SOL funding rate -0.0222% - SHORT SQUEEZE SETUP

VIX at 19.4 - CAUTION territory

VIX at 21.5 - CAUTION territory

VIX at 20.6 - CAUTION territory

VIX at 22.2 - CAUTION territory

Financial conditions loosening - NFCI at -0.51, liquidity supportive

OSINT: Canada proposes ban on social media for under‑16s

DXY +0.31% - dollar strength signal

DXY RSI 70.6 - overbought (crossed above 70)

DXY RSI 70.2 - overbought (crossed above 70)